Get the Stockscreener App
2.05
2.57%
0.07
Elutia Inc stock is traded at $2.05, with a volume of 20,641.
It is up +2.57% in the last 24 hours and up +12.83% over the past month.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
See More
Previous Close:
$1.98
Open:
$1.95
24h Volume:
20,641
Relative Volume:
0.55
Market Cap:
$81.82M
Revenue:
$24.38M
Net Income/Loss:
$-53.95M
P/E Ratio:
-0.83
EPS:
-2.47
Net Cash Flow:
$-23.31M
1W Performance:
+17.39%
1M Performance:
+12.83%
6M Performance:
-45.70%
1Y Performance:
-56.60%
1-Day Range:
$1.95
$2.13
1-Week Range:
$1.72
$2.17
52-Week Range:
$1.61
$5.1499
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
2.05 | 81.82M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
136.02 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.04 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
397.38 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.33 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.23 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price - simplywall.st
Elutia Inc. (NASDAQ:ELUT) Shares Purchased by Millennium Management LLC - Defense World
Citadel Advisors LLC Acquires Shares of 22,431 Elutia Inc. (NASDAQ:ELUT) - Defense World
Brokers Issue Forecasts for Elutia FY2026 Earnings - Defense World
Elutia (NASDAQ:ELUT) Shares Down 1% – Time to Sell? - Defense World
Aziyo Biologics Holds Annual Stockholders Meeting - TipRanks
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET By Investing.com - Investing.com South Africa
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET - Investing.com
Elutia v. Medtronic: Delaware court rules on indemnity and insurance obligations in FiberCel lawsuit - Insurance Business America
ELUT stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
ELUT stock touches 52-week low at $1.61 amid market challenges - Investing.com India
Elutia Inc. Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method - marketscreener.com
Elutia announces publication of article on measuring antibiotic release - TipRanks
Elutia (ELUT) Innovates with New Antibiotic Release Method | ELUT Stock News - GuruFocus
Revolutionary Drug Testing Method Cuts Medical Device Development Time from 14 Days to Just 30 Hours - Stock Titan
FY2025 EPS Estimates for Elutia Lifted by Cantor Fitzgerald - Defense World
Lake Street Capital Has Lowered Expectations for Elutia (NASDAQ:ELUT) Stock Price - Defense World
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock N - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Sto - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Stock News - GuruFocus
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock News - GuruFocus
Elutia Q1 2025 slides: EluPro sales surge 84% amid overall revenue decline - Investing.com Nigeria
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition - Yahoo Finance
Elutia Inc. Reports Strong Growth in EluPro Sales - TipRanks
Earnings call transcript: Elutia Q1 2025 beats EPS forecast, stock rises - Investing.com
SEC Form 424B5 filed by Elutia Inc. - Quantisnow
Elutia Inc Reports Q1 2025 Earnings: EPS of -$0.21 Meets Estimates, Revenue of $3.1 Million Misses Estimates - GuruFocus
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - The Manila Times
Elutia Inc (ELUT) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Renaissance Technologies LLC Sells 11,700 Shares of Elutia Inc. (NASDAQ:ELUT) - Defense World
Elutia Inc. Ends Distribution Agreement with LeMaitre - TipRanks
Elutia Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Aziyo Biologics (ELUT) Receives a New Rating from Lake Street - The Globe and Mail
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | ELUT Stock News - GuruFocus
Elutia (ELUT) Resumes Direct Control Over Cardiovascular Portfol - GuruFocus
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - The Manila Times
Elutia Ends LeMaitre Partnership: Strategic Shift Promises 80% Margins in $2.9M Cardiovascular Line - Stock Titan
Elutia Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - The Manila Times
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Ou - GuruFocus
Elutia to Participate in Chardan's Trending Issues in Drug Devel - GuruFocus
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elutia Inc Stock (ELUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HighCape Capital, L.P. | Director |
Feb 03 '25 |
Buy |
2.50 |
420,000 |
1,050,000 |
9,520,232 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Jul 31 '24 |
Option Exercise |
1.43 |
105,080 |
150,002 |
257,823 |
4.43%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):